Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be presenting at the Rodman & Renshaw 18 th Annual
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2016 Results
SOLANA BEACH, Calif., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced its financial results for the second quarter ended June 30, 2016.
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results
SOLANA BEACH, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter 2016 on Monday, August 15, 2016,
View HTML
Toggle Summary Evoke Pharma Completes Credit Facility Repayment
SOLANA BEACH, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and
View HTML
Toggle Summary Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
SOLANA BEACH, Calif., July 29, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company"), today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10
View HTML
Toggle Summary Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
SOLANA BEACH, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the US Food and Drug Administration (FDA) has conditionally accepted the proprietary brand
View HTML
Toggle Summary Evoke Pharma Announces $4.5 Million At-The-Market Offering
SOLANA BEACH, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for an
View HTML
Toggle Summary Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
SOLANA BEACH, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic
View HTML
Toggle Summary Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
SOLANA BEACH, Calif. , July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead
View HTML
Toggle Summary Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
SOLANA BEACH, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead
View HTML